• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Paroxysmal Supraventricular Tachycardia Market

    ID: MRFR/MED/4462-HCR
    100 Pages
    Kinjoll Dey
    September 2025

    Paroxysmal Supraventricular Tachycardia (PSVT) Market: by Type (AVNRT, AVRT, PAT, WPW) Diagnosis (EPS, Echocardiogram, Holter Monitor, Event Monitor) Treatment (Physical Maneuvers, medications), End-User (Hospitals & Clinics) - Forecast Till 2032

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Paroxysmal Supraventricular Tachycardia Market Research Report – Forecast to 2032 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Paroxysmal Supraventricular Tachycardia Market Summary

    The Global Paroxysmal Supraventricular Tachycardia (PSVT) Market is projected to grow significantly from 0.3 USD Billion in 2024 to 0.62 USD Billion by 2035.

    Key Market Trends & Highlights

    Paroxysmal Supraventricular Tachycardia (PSVT) Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 6.89 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 0.62 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 0.3 USD Billion, laying a solid foundation for future expansion.
    • Growing adoption of advanced treatment options due to increasing awareness of PSVT is a major market driver.

    Market Size & Forecast

    2024 Market Size 0.3 (USD Billion)
    2035 Market Size 0.62 (USD Billion)
    CAGR (2025-2035) 6.89%

    Major Players

    GlaxoSmithKline PLC (U.K.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), AstraZeneca PLC (U.K.), Teva pharmaceutical industries (Israel), Sanofi SA (France), Medtronic, Inc. (U.S.), Glenmark Pharmaceuticals (U.S.), St. Jude Medical, Inc. (U.S.), BIOTRONIK SE & Co. KG (U.S.), GE Healthcare (U.S.), Boston Scientific Corporation (U.S.), Abbott Laboratories Inc. (U.S.), (Alcon) Novartis (U.S.), Siemens AG (Germany), Koninklijke Philips N.V. (U.S.)

    Paroxysmal Supraventricular Tachycardia Market Drivers

    Aging Population

    The demographic shift towards an aging population is a significant driver of the Global Paroxysmal Supraventricular Tachycardia (PSVT) Market Industry. Older adults are more susceptible to cardiovascular conditions, including PSVT, due to age-related physiological changes. As the global population ages, the incidence of PSVT is likely to rise, leading to increased demand for treatment options. This trend is particularly evident in developed countries, where healthcare systems are adapting to cater to the needs of older patients. Consequently, the market is poised for growth as healthcare providers focus on managing PSVT in this demographic.

    Rising Incidence of PSVT

    The Global Paroxysmal Supraventricular Tachycardia (PSVT) Market Industry is witnessing a notable increase in the incidence of PSVT, driven by factors such as lifestyle changes and increased stress levels. As more individuals experience episodes of rapid heart rate, the demand for effective treatment options rises. In 2024, the market is valued at approximately 0.3 USD Billion, reflecting the growing awareness and diagnosis of this condition. This trend is expected to continue, with projections indicating a market value of 0.62 USD Billion by 2035, suggesting a robust growth trajectory fueled by the rising prevalence of PSVT.

    Market Growth Projections

    The Global Paroxysmal Supraventricular Tachycardia (PSVT) Market Industry is projected to experience substantial growth over the next decade. With a market valuation of 0.3 USD Billion in 2024, it is expected to reach 0.62 USD Billion by 2035, reflecting a compound annual growth rate (CAGR) of 6.89% from 2025 to 2035. This growth is indicative of the increasing recognition of PSVT as a significant health issue and the corresponding demand for effective treatment options. The market dynamics suggest a favorable environment for stakeholders, including healthcare providers and pharmaceutical companies, to engage in the development and distribution of PSVT therapies.

    Increased Awareness and Diagnosis

    There is a growing awareness regarding cardiovascular diseases, including PSVT, which is positively influencing the Global Paroxysmal Supraventricular Tachycardia (PSVT) Market Industry. Public health campaigns and educational initiatives are helping to inform both healthcare professionals and patients about the symptoms and risks associated with PSVT. This heightened awareness leads to earlier diagnosis and treatment, which is essential for effective management of the condition. As a result, the market is expected to see substantial growth, with a projected compound annual growth rate (CAGR) of 6.89% from 2025 to 2035, indicating a sustained interest in addressing this health concern.

    Advancements in Treatment Modalities

    Innovations in medical technology are significantly impacting the Global Paroxysmal Supraventricular Tachycardia (PSVT) Market Industry. New treatment modalities, including catheter ablation and advanced antiarrhythmic drugs, are emerging, offering patients more effective and less invasive options. These advancements not only enhance patient outcomes but also contribute to the overall growth of the market. The introduction of novel therapies is likely to attract more patients seeking relief from PSVT symptoms, thereby expanding the market. As the industry evolves, it is anticipated that these innovations will play a crucial role in shaping the future landscape of PSVT treatment.

    Regulatory Support for New Therapies

    Regulatory bodies are increasingly supportive of the development and approval of new therapies for PSVT, which is fostering growth in the Global Paroxysmal Supraventricular Tachycardia (PSVT) Market Industry. Streamlined approval processes and incentives for innovation are encouraging pharmaceutical companies to invest in research and development of novel treatment options. This regulatory environment not only accelerates the availability of new therapies but also enhances competition within the market. As a result, patients benefit from a wider array of treatment choices, which is likely to drive market expansion in the coming years.

    Key Companies in the Paroxysmal Supraventricular Tachycardia Market market include

    Future Outlook

    Paroxysmal Supraventricular Tachycardia Market Future Outlook

    The Global Paroxysmal Supraventricular Tachycardia (PSVT) Market is projected to grow at a 6.89% CAGR from 2024 to 2035, driven by advancements in treatment options and increasing patient awareness.

    New opportunities lie in:

    • Develop innovative digital health solutions for remote monitoring of PSVT patients.
    • Invest in research for novel antiarrhythmic drugs targeting PSVT.
    • Expand partnerships with healthcare providers to enhance patient education and management programs.

    By 2035, the PSVT market is expected to exhibit robust growth, reflecting advancements in treatment and increased patient engagement.

    Market Segmentation

    Intended Audience

    • Potential Investors
    • Market Research and Consulting Service Providers
    • Academic Medical Institutes and Universities
    • Medical Research Laboratories
    • Research and Development (R&D) Companies
    • Hospitals and Clinics
    • Imaging Device Manufacturers
    • Paroxysmal Supraventricular Tachycardia Treatment Providers
    • Paroxysmal Supraventricular Tachycardia Drug Manufacturers and Suppliers

    Paroxysmal Supraventricular Tachycardia (PSVT) Market Scenario

    • Potential Investors
    • Market Research and Consulting Service Providers
    • Academic Medical Institutes and Universities
    • Medical Research Laboratories
    • Research and Development (R&D) Companies
    • Hospitals and Clinics
    • Imaging Device Manufacturers
    • Paroxysmal Supraventricular Tachycardia Treatment Providers
    • Paroxysmal Supraventricular Tachycardia Drug Manufacturers and Suppliers

    Paroxysmal Supraventricular Tachycardia (PSVT) Market Key Players

    • Koninklijke Philips N.V. (U.S.)
    • Siemens AG (Germany)
    • (Alcon) Novartis (U.S.)
    • Abbott Laboratories Inc. (U.S.)
    • Boston Scientific Corporation (U.S.)
    • GE Healthcare (U.S.)
    • BIOTRONIK SE & Co. KG (U.S.)
    • St. Jude Medical, Inc. (U.S.)
    • Glenmark Pharmaceuticals (U.S.)
    • Medtronic, Inc. (U.S.)
    • Sanofi SA (France)
    • Teva pharmaceutical industries (Israel)
    • AstraZeneca PLC (U.K.)
    • Pfizer, Inc. (U.S.)
    • Novartis AG (Switzerland)
    • GlaxoSmithKline PLC (U.K.)

    Report Scope

    Report Attribute/Metric Details
    Market Size 2023 0.28 (USD Billion)
    Market Size 2024 0.30 (USD Billion)
    Market Size 2032 0.52 (USD Billion)
    Compound Annual Growth Rate (CAGR) 6.3 % (2024 - 2032)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2023
    Market Forecast Period 2024 - 2032
    Historical Data 2019 - 2023
    Forecast Units Value (USD Billion)
    Segments Covered Type, Application, and End-User
    Geographies Covered North America, Europe, Asia-Pacific, and Rest of the World (RoW)
    Key Vendors GlaxoSmithKline PLC, Novartis AG, Pfizer, Inc., AstraZeneca PLC, Teva Pharmaceutical Industries, Sanofi SA, Medtronic, Inc., Glenmark Pharmaceuticals, St. Jude Medical, Inc., BIOTRONIK SE & Co. KG, GE Healthcare, Boston Scientific Corporation, Abbott Laboratories Inc., (Alcon) Novartis, Siemens AG, Koninklijke Philips N.V.
    Key Market Opportunities Increasing government support, rising investments in healthcare, and the presence of a well-established pharmaceutical market
    Key Market Drivers Increasing applications of treatments and diagnostics in heart disorders are expected to drive market growth

    Market Highlights

    Author
    Kinjoll Dey
    Research Analyst Level I

    He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

    Leave a Comment

    FAQs

    What is Paroxysmal Supraventricular Tachycardia?

    Supraventricular tachycardia is a condition where there is a rapid increase in the heart rate caused by electrical impulses originating above the heart. Paroxysmal supraventricular tachycardia, also known as PSVT, is a condition wherein the patient shows an irregularity in heartbeats.

    What is the CAGR of the Paroxysmal Supraventricular Tachycardia Market?

    Paroxysmal Supraventricular Tachycardia Market is expected to exhibit a strong 6.30% CAGR over the forecast period from 2024 to 2032.

    What is the major driver for the Paroxysmal Supraventricular Tachycardia Market?

    Growing prevalence of cardiovascular diseases is the major driver for the Paroxysmal Supraventricular Tachycardia Market.

    Which is the major regional Paroxysmal Supraventricular Tachycardia Market?

    The Americas dominate the global Paroxysmal Supraventricular Tachycardia Market.

    What are the key players in the Paroxysmal Supraventricular Tachycardia Market?

    Leading players in the Paroxysmal Supraventricular Tachycardia Market include GSK, Novartis, and Pfizer, among others.

    Paroxysmal Supraventricular Tachycardia Market Research Report – Forecast to 2032 Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials